|

Biomarker Test Next Step for New Mesothelioma Drug

ByAlex Strauss

scientist

A company that makes stem cell-focused treatments for cancer has taken an important step closer to testing a promising new mesothelioma drug.

The biopharmaceutical company Verastem, Inc. specializes in agents that destroy cancer by killing cancer stem cells. One of its lead medicines is VS-6063, a focal adhesion kinase inhibitor scheduled to be the subject of a mesothelioma study later this year. In a Phase I safety study of 36 patients conducted by Pfizer (original developers of VS-6063), the drug was “well-tolerated” and showed enough efficacy to warrant further, larger studies.

A focal adhesion kinase (FAK) inhibitor is an agent that regulates the growth and spread of tumor cells by inhibited a crucial signaling pathway. In preclinical cancer models, when this pathway is disrupted, there is a noticeable reduction in cancer stem cells, primary tumor mass, and metastasis.  Verastem co-founder and chair of the Scientific Advisory Board, Robert Weinberg, Ph.D., said earlier this year, “Verastem has identified the FAK pathway as a critical regulator of the survival of cancer stem cells, which are an underlying cause of cancer recurrence and metastasis.”

Now, the new drug may be a step closer to reality for mesothelioma patients. Verastem has contracted with LabCorp, Inc. to validate biomarkers for VS-6063. It is estimated that about half of mesothelioma patients are lacking a particular tumor suppressor, a fact which could make them more significantly more sensitive to FAK inhibitors like VS-6063. It will be LabCorp’s job to develop a test for that biomarker, which will then help Verastem identify mesothelioma patients for the upcoming clinical trial of VS-6063. The company calls such a test “an integral component” of undergoing the FDA approval process. They have announced plans to run multiple clinical trials of VS-6063 in 2013, including what they call a “potentially pivotal study in mesothelioma”.

According to the Centers for Disease Control and Prevention (CDC), approximately 2,000 to 3,000 cases of malignant mesothelioma are diagnosed in the U.S. each year.  This cancer is caused by asbestos, a naturally occurring carcinogenic mineral that has been used in thousand of products and applications. Conventional cancer treatments have done little to improve the prognosis for mesothelioma patients, which is typically poor.

Sources:

“Verastem Enters Biomarker Agreement with LabCorp for Cancer Stem Cell Agent Companion Diagnostic”, Press Release, January 9, 2013, Wall Street Journal Marketwatch.
“Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer”, July 11, 2012, Press Release distributed by Reuters.

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    ByAlex Strauss

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…